Immunotherapy

Article	Citations
Immortal Time Bias in the Association Between Toxicity and Response for Immune Checkpoint Inhibitors: A Meta-Analysis	93
Pasotuxizumab, a Bite ® Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings	83
Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait	68
A Global Picture: Therapeutic Perspectives for COVID-19	57
Systemic Immune–Inflammation Index Predicts Prognosis of Cancer Immunotherapy: Systemic Review and Meta-Analysis	47
Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma	45
TYK2 as a Therapeutic Target in the Treatment of Autoimmune and Inflammatory Diseases	35
Immune Checkpoint Inhibitors and Chemotherapy in First-Line NSCLC: a Meta-Analysis	35
Tumor Cell-Based Vaccine: An Effective Strategy for Eradication of Cancer Cells	33
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma	31
Antimicrobial/Anticancer Peptides: Bioactive Molecules and Therapeutic Agents	31
Cytokine Storm Modulation in COVID-19: A Proposed Role for Vitamin D and DPP-4 Inhibitor Combination Therapy (VIDPP-4i)	31
Immunotherapy for Gastric Cancer: A 2021 Update	27
Therapeutics to Tackle Omicron Outbreak	27
Sutimlimab for Treatment of Cold Agglutinin Disease: Why, How And For Whom?	27
Production of Hyperimmune Anti-SARS-CoV-2 Intravenous Immunoglobulin from Pooled COVID-19 Convalescent Plasma	26
Peripheral Blood Eosinophil Count is Associated with Response to Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer	25
Atherosclerosis: Immunopathogenesis and Strategies for Immunotherapy	23
Blocking Egfr with Nimotuzumab: A Novel Strategy for Covid-19 Treatment	22
Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer	22
Targeted Allergen-Specific Immunotherapy within the Skin Improves Allergen Delivery to Induce Desensitization to Peanut	21
Successful Use of Secukinumab in Two Melanoma Patients with Immune Checkpoint Inhibitor-Induced Inflammatory Arthropathy	19
PD-L1 Expression as a Predictive Biomarker For Immune Checkpoint Inhibitors: Between a Dream And a Nightmare	18
Phase I Studies of Peptide Vaccine Cocktails Derived from GPC3, WDRPUH and NEIL3 for Advanced Hepatocellular Carcinoma	17
The Rationale for Targeting the JAK/STAT Pathway in Scleroderma-Associated Interstitial Lung Disease	17

Chimeric Antigen Receptor Macrophage for Glioblastoma Immunotherapy: The Way Forward	17
Emerging Advances in Cationic Liposomal Cancer Nanovaccines: Opportunities and Challenges	17
Hematological Prognosticators in Metastatic Renal Cell Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis	16
Overcoming Stromal Barriers to Immuno-Oncological Responses via Fibroblast Activation Protein-Targeted Therapy	15
Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small-Cell Lung Cancer: ALCHEMIST Chemo-Io (ACCIO)	15
Immune Checkpoint Inhibitors for Brain Metastases in Non-Small-Cell Lung Cancer: From Rationale to Clinical Application	15
Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer	15
Immunity to Glycan α-Gal and Possibilities for the Control of COVID-19	15
Development of Hepatitis Triggered by SARS-CoV-2 Vaccination in Patient with Cancer During Immunotherapy: A Case Report	15
Cellular Immunotherapy in Gastric Cancer: Adoptive Cell Therapy and Dendritic Cell-Based Vaccination	14
Immune Checkpoint Inhibitors Use and Effects on Prognosis of COVID-19 Infection: A Systematic Review and Meta-Analysis	14
Safety of Semi-Depot House Dust Mite Allergen Extract in Children and Adolescents with Allergic Rhinitis and Asthma	14
Immunotherapy for Cholangiocarcinoma: a 2021 Update	13
Use of Immune Checkpoint Inhibitors in Cancer Patients with Pre-Existing Sarcoidosis	13
Capillary-Leak Syndrome: An Unrecognized Early Immune Adverse Effect of Checkpoint-Inhibitors Treatment	13
Efficacy of immunotherapy in KRAS -mutant non-small-cell lung cancer with comutations	13
Anti-PD-1 Treatment-Induced Immediate Central Diabetes Insipidus: A Case Report	13
A Review of Secukinumab in Psoriasis Treatment	12
Pegcetacoplan Treatment for Geographic Atrophy Due to Age-Related Macular Degeneration: A Plain Language Summary of the FILLY Study	12
Immunotherapy in Psoriasis	12
Immunotherapy in Hematological Malignancies: Recent Advances and Open Questions	12
Nivolumab-Induced Systemic Capillary Leak Syndrome as an Ultra Rare Life-Threatening Phenomenon of Late Toxicity and Intravenous Immunoglobulin Efficacy	12
The Safety and Efficacy of Immune-Checkpoint Inhibitors in Patients with Cancer and Pre-Existing Autoimmune Diseases	11
Sargramostim and Immune Checkpoint Inhibitors: Combinatorial Therapeutic Studies in Metastatic Melanoma	10
Front-Line Daratumumab-VTd Versus Standard-of-Care in ASCT-Eligible Multiple Myeloma: Matching-Adjusted Indirect Comparison	10
Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review	10
Immunology of Osteoporosis: Relevance of Inflammatory Targets for the Development of Novel Interventions	10
Immune Checkpoint Inhibitors in Luminal Gastrointestinal Malignancies: Going Beyond MSI-H/dMMR, TMB and PD-L1	9
Overview of Subcutaneous Immunoglobulin 16.5% in Primary and Secondary Immunodeficiency Diseases	9
Surrogate end Points for Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors	9
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?	9
Effectiveness of Durvalumab Consolidation in Stage III Non-Small-Cell Lung Cancer: Focus on Treatment Selection and Prognostic Factors	9
Immune-Checkpoint Inhibitors in Renal Transplanted Patients Affected by Melanoma: A Systematic Review	9
Chemotherapy or Chemo-Immunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer: A Meta-Analysis	9
Immune Cells and Signatures Characterize Tumor Microenvironment and Predict Outcome in Ovarian and Endometrial Cancers	9
An Anti-CD6 Antibody for the Treatment of COVID-19 Patients with Cytokine-Release Syndrome: Report of Three Cases	9
The Effect of Low-Dose Chemotherapy on the Tumor Microenvironment and its Antitumor Activity Combined with Anti-PD-1 Antibody	9
Clinical Efficacy of Immune Checkpoint Inhibitors in Patients with Brain Metastases	9
Comparing Abrocitinib and Dupilumab in the Treatment of Atopic Dermatitis: A Plain Language Summary	8
The Mrna Covid-19 Vaccine In Patients with Cancer Receiving Checkpoint Inhibitor Therapy: What we Know And What We Don’T	8
Immunoregulatory T cell Epitope Peptides for the Treatment of Allergic Disease	8
Toxic Epidermal Necrolysis Associated with Chemoimmunotherapy For Lymphoma: Case Report and Literature Review	8
Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma	8
Different Clinical Significance of Novel B7 Family Checkpoints VISTA and HHLA2 in Human Lung Adenocarcinoma	8
Real-World Treatment Patterns and Outcomes in PD-L1-Positive Non-Small Cell Lung Cancer	8
Pembrolizumab-Associated Erythema Nodosum in the Treatment of Metastatic Melanoma	8
Clinical Efficacy and Safety of Efgartigimod for Treatment of Myasthenia Gravis	8
Therapeutic Cancer Vaccine Therapy for Acute Myeloid Leukemia	8
Determinants of Treatment for First-Line Immune-Based Combinations in Metastatic Renal Cell Carcinoma: a Critical Overview of Recent Evidence	8
Immunotherapy Versus Standard Chemotherapy For Treatment of Extensive-Stage Small-Cell Lung Cancer: A Systematic Review	8

IL-13 Antagonists in the Treatment of Atopic Dermatitis	7
Efficacy and Safety of Chimeric Antigen Receptor T Cell Immunotherapy in B-Cell Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis	7
Treatment of EAE Mice with Treg, G-MDSC and IL-2: a New Insight into Cell Therapy for Multiple Sclerosis	7
Acute Interstitial Nephritis and PR3-ANCA Following Reintroduction of Pembrolizumab: A Case Report	7
Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma	7
A New Perspective on The Potential Application of Ripk1 in the Treatment of Sepsis	7
Hurdles for the Wide Implementation of Photoimmunotherapy	7
Real-world Maintenance Therapy and Survival Outcomes For Pembrolizumab Plus Pemetrexed and Platinum for Non-Small-Cell Lung Cancer in USA	7
Hla Loss of Heterozygosity-Mediated Discordant Responses to Immune Checkpoint Blockade in Squamous Cell Lung Cancer with Renal Metastasis	7
Chimeric Antigen Receptor T cells Immunotherapy: Challenges and Opportunities in Hematological Malignancies	7
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice	7
Combined Application of Bevacizumab and Pd-1 Blockade Displays Durable Treatment Effects by Increasing the Infiltration And Cytotoxic Function of Cd8 + T Cells in Lu	7
Secondary Pneumothorax During Immunotherapy in two Patients with Metastatic Solid Tumors; a New Entity	7
Managing Viral Hepatitis in Cancer Patients Under Immune Checkpoint Inhibitors: Should we Take the Risk?	7
Lichenoid Drug Eruption on the Lower Lip Caused by Anti-PD-1 Monoclonal Antibody: A Case Report and Literature Review	6
Vanishing Bile Duct Syndrome Following Pembrolizumab Infusion: Case Report and Review of the Literature	6
Upadacitinib for Moderate to Severe Atopic Dermatitis	6
First-Line Treatment of Advanced/Metastatic Melanoma with Anti-PD-1 Antibodies: Multicenter Experience in Poland	6
Harnessing Gene Fusion-Derived Neoantigens for ‘Cold’ Breast and Prostate Tumor Immunotherapy	6
Lights and Shadows on the Role of Rhg-CSF in Cancer Patients During the COVID-19 Pandemic and Future Perspectives of Research	6
Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, Myasthenia Gravis and Transaminitis: A Case Series and Review	6
Barriers and Solutions to Improve Access for Chimeric Antigen Receptor Therapies	6
Body Composition and Inflammation Impact in Non-Small-Cell Lung Cancer Patients Treated by First-line Immunotherapy	6
Patient Needs and Benefits of Sublingual Immunotherapy for Grass Pollen-Induced Allergic Rhinitis: An Observational Study	6
Small-Cell Breast Carcinoma with Response to Atezolizumab: A Case Report	6
Delayed Immune-Related Neutropenia with Hepatitis By Pembrolizumab	6
Targeting the Tumor Microenvironment of Ewing Sarcoma	6
Urothelial Carcinoma in The Era of Immune Checkpoint Inhibitors	6
Tocilizumab in Grade 4 Hepatitis Secondary to Immune Checkpoint Inhibitor: A Case Report and Review of the Literature	6
Volume Increase of Spleen in Melanoma Patients Undergoing Immune Checkpoint Blockade	6
Plasmodium Falciparum -Infected Humanized Mice: A Viable Preclinical Tool	6
GO-BEYOND: A Real-World Study of Persistence of Golimumab in Patients with Axial Spondyloarthritis and Rheumatoid Arthritis in Turkey	6
Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics	6
Etrasimod for the Treatment of Ulcerative Colitis	6
Cost–Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer	6
Secukinumab in the Treatment of Hidradenitis Suppurativa	6
Subcutaneous Immunoglobulin Use in Immunoglobulin-Naive Patients with Primary Immunodeficiency: A Systematic Review	6
Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors	6
Evaluation of PD-L1 as a Biomarker for Immunotherapy for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis	6
Abscopal Effect of Radiation Therapy and Nivolumab in a Patient with Combined Small-Cell Lung Cancer: A Case Report	6
A CD123-Specific Chimeric Antigen Receptor Augments Anti-Acute Myeloid Leukemia Activity of Vγ9Vδ2 T Cells	5
Appropriate use of Antimicrobial Therapy For COVID-19 Co-Infection	5
Safety and Efficacy of Mutant Neoantigen-Specific T-Cell Treatment Combined Anti-Pd-1 Therapy in Stage Iv Solid Tumors	5
Rechallenge of Anti-PD-1/PD-L1 Antibody Showed a Good Response to Metastatic Breast Cancer: A Case Report	5
Association of Immune-Related Adverse Events and Efficacy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis	5
Mesenchymal Stem Cells Derived from Human Dental Follicle Modulate the Aberrant Immune Response in Atopic Dermatitis	5
Under-Prescription of Allergen-Immunotherapy: Why is it Important to Prescribe it in Childhood Instead?	5
Anti-PD-1 and Regorafenib Induce Severe Multisystem Adverse Events in Microsatellite Stability Metastatic Colorectal Cancer: A Case Report	5
Takotsubo Syndrome in a Patient with Metastatic Renal Cell Carcinoma Treated with Pembrolizumab Plus Axitinib	5
Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults	5
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis	5
Effectiveness of COVID-19 Vaccines Against Omicron Variant	5
Potential Biomarkers and Resistance Mechanisms of Atezolizumab in a Patient with Lung Squamous Cell Carcinoma	5
Long-Term Immune-Related Adverse Events after Discontinuation of Immunotherapy	5
Unconventional Radiotherapy to Enhance Immunotherapy Efficacy in Bulky Tumors: A Case Report	5
Antibody Therapy Against Antibiotic-Resistant Diarrheagenic Escherichia Coli : A Systematic Review	5
Adherence to Subcutaneous Biological Therapies in Patients with Inflammatory Rheumatic Diseases and Inflammatory Bowel Disease: A Systematic Review	5
Pembrolizumab-Induced Follicular Eruption and Response to Isotretinoin	5
Mechanisms of Allergen Immunotherapy Supporting its Disease-Modifying Effect	5
Herpes Zoster in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors	5
Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center	5
Mirna Profiles Change During Grass Pollen Immunotherapy Irrespective of Clinical Outcome	5
Systemic IgG Exposure and Safety in Patients with Primary Immunodeficiency: A Randomized Crossover Study Comparing a Novel Investigational Wearable Infusor Versus the Crono Pump	5
A Case of Successful Pembrolizumab Rechallenge in a Patient with Non-Small-Cell Lung Cancer and Grade 3 Dermatomyositis	5
Galectin-9 and PD-L1 Antibody Blockade Combination Therapy Inhibits Tumour Progression in Pancreatic Cancer	5
BET Inhibitors: the Promise of a New Generation of Immunotherapy in Glioblastoma	5
Treatment of Children with Primary Immunodeficiencies with a Subcutaneous Immunoglobulin 16.5% (Cutaquig ®  [Octanorm])	5
Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis	5
Safety and Effectiveness of the 300 IR Sublingual House Dust Mite Allergen Immunotherapy Tablet: 2-Year Interim Analysis of a Specified Drug-Use Survey	5
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)	5
Use of Upadacitinib in the Treatment of Psoriatic Arthritis	5
Clinical Course and Management of Pembrolizumab-Associated Isolated Adrenocorticotrophic Hormone Deficiency: A New Case and Literature Review	5
Immunotherapy in Atopic Dermatitis	5
Validation of a Drug-Based Score in Advanced Urothelial Carcinoma Treated with Pembrolizumab	5
Immune Checkpoint Inhibitor-Induced Autoimmune Encephalitis in Metastatic Squamous Cell Lung Cancer	5
Three Decades of Clinical Trials on Immunotherapy for Human Leishmaniases: a Systematic Review and Meta-Analysis	4
Real-World Study: Drug Reduction in Children With Allergic Rhinitis and Asthma Receiving Immunotherapy	4
How Bilastine is Used to Treat Allergic Rhinitis and Urticaria in Children	4
Mesenchymal Stem Cell Treatment for Hyperactive Immune Response in Patients with COVID-19	4
4-1BB Antibody Enhances Cytotoxic Activity of Natural Killer Cells Against Prostate Cancer Cells Via NKG2D Agonist Combined with IL-27	4

Uveitis Associated with Cancer Immunotherapy: Long-Term Outcomes	4
Durable Response After Immune Checkpoint Inhibitor-Related Diabetes in Mismatch Repair-Deficient Pancreatic Cancer	4
Indications and Effects of Biological Agents in the Treatment of Noninfectious Uveitis	4
Hypermutation as a Potential Predictive Biomarker of Immunotherapy Efficacy in High-Grade Gliomas: A Broken Dream?	4
Overcoming Immune-Resistance in Laryngeal Cancer: A Case Report of the Abscopal Effect and Nivolumab Beyond Progression	4
Durvalumab in Advanced Cholangiocarcinoma: Is Someone Knocking Down the Door?	4
The Latest Developments in Biomarkers Predicting Response to Immunotherapy	4
Emerging Advances in Nanomedicine for Breast Cancer Immunotherapy: Opportunities and Challenges	4
Abscopal Effect and Resistance Reversion in Nivolumab-Treated Non-Small-Cell Lung Cancer Undergoing Palliative Radiotherapy: A Case Report	4
Reversing Chemokine/Chemokine Receptor Mismatch to Enhance the Antitumor Efficacy of CAR-T Cells	4
Infrequent Liver Injury from Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma	4
Vaccines and Immune Checkpoint Inhibitors: a Promising Combination Strategy in Gastrointestinal Cancers	4
Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan	4
Nimotuzumab for COVID-19: Case Series	4
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma	4
Restricted Mean Survival Time as Outcome Measure in Advanced Urothelial Bladder Cancer: Analysis of 4 Clinical Studies	4
Current Status and Future Development of anti-HIV Chimeric Antigen Receptor T-cell Therapy	4
The Role of Upadacitinib on the Treatment of Ulcerative Colitis	4
Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases	4
Pd-1/L1 Inhibitors May Increase the Risk of Pericardial Disease in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis and Systematic Review	4
Efficacy of Therapies Targeting TGF-β in Solid Tumors: a Systematic Review and Meta-Analysis of Clinical Trials	4
Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy	4
PD-L1 ≥ 50% Lung Cancer Refractory to PD-1 Inhibition: The Role of Salvage Chemo-Immunotherapy Combination	4
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer	4
Enteric Plexus Neuropathy Associated with PD-L1 Blockade in a Patient with Small-Cell Lung Cancer	4
Immune Checkpoint Inhibitors and Combinations with Other Agents in Cholangiocarcinoma	4
Dupilumab Facial Redness: Histologic Characterization on a Series of four Cases	4
Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature	4
Reply to the Letter ‘ Effectiveness of COVID-19 Vaccines against Omicron Variant’	4
Predicting Immune Checkpoint Inhibitor Response with Mathematical Modeling	3
The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease	3
No Association Between BMI and Immunotoxicity or Clinical Outcomes for Immune Checkpoint Inhibitors	3
Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis	3
Late-Onset Toxicities of Monoclonal Antibodies in Cancer Patients	3
Safety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic	3
Clinical Predictors of Chimeric Antigen Receptor T-Cell Therapy Neurotoxicity: A Single-Center Study	3
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study	3
Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Acute and Chronic Steroid-Refractory Gvhd Mouse Models	3
Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So €˜Pure’	3
Super-Refractory Status Epilepticus During Blinatumomab Initiation for B-Cell Acute Lymphoblastic Leukemia	3
Toripalimab and Anlotinib as a Maintenance Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report	3
What Role will Ensifentrine Play in the Future Treatment of Chronic Obstructive Pulmonary Disease Patients? Implications from Recent Clinical Trials	3
FHL1 As a Novel Prognostic Biomarker and Correlation with Immune Infiltration Levels in Lung Adenocarcinoma	3
Immunotherapeutic Approach for Advanced Pancreatic Adenocarcinoma	3
Ixekizumab in the Treatment of Psoriatic Arthritis	3
Tezepelumab: An Anti-Thymic Stromal Lymphopoietin Monoclonal Antibody for the Treatment of Asthma	3
Impact of Helicobacter Pylori Infection on The Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis	3
Checkpoint Inhibitors in BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Can they Help Spare the Bladder?	3
A case of late and lethal Trousseau’s syndrome induced by pembrolizumab in lung adenocarcinoma	3
Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review	3
Indirect Comparison of Pembrolizumab Monotherapy Versus Nivolumab + Ipilimumab in First-Line Metastatic Lung Cancer	3
A Review of Phase Iii Clinical Trials of Us Fda-Approved Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyposis	3
Low-Dose or -Number of BCG in Non-Muscle Invasive Bladder Cancer: Updated Systematic Review and Meta-Analysis	3
Pretreatment Lung Immune Prognostic Index as a Biomarker in Advanced Non-Small-Cell Lung Cancer Patients Receiving First Line Pembrolizumab	3
Adenovirus-Induced Hemorrhagic Cystitis After CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in a Patient with Large B-Cell Lymphoma	3
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis	3
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives	3
Immune Checkpoint Inhibitors for Advanced or Metastatic Basal Cell Carcinoma: How much Evidence do we Need?	3
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY	3
Keeping it Real: Implications of Real-World Treatment Outcomes for First-Line Immunotherapy in Metastatic Non-Small-Cell Lung Cancer	3
The Dilemma of Neoadjuvant and Adjuvant Therapy in Urothelial Carcinoma: will Immunotherapy Solve the Problem?	3
Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Chemotherapy for Advanced Pancreatic Cancer	3
Cost–Effectiveness Analysis of Nivolumab Plus Cabozantinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma	3
Sintilimab Plus Sorafenib: A novel Regimen for Hepatocellular Carcinoma	3
Combining in Situ Vaccination and Immunogenic Apoptosis to Treat Cancer	3
Durable Complete Remission of Leptomeningeal Melanoma by Intrathecal Methotrexate Maintained with Systemic Ipilimumab	3
Reduced Risk of Infections with the Intravenous Immunoglobulin, IgPro10, in Patients at Risk of Secondary Immunodeficiency-Related Infections	3
A Meta-Analysis of Application of Pd-1/Pd-L1 Inhibitor-Based Immunotherapy in Unresectable Locally Advanced Triple-Negative Breast Cancer	3
Complete Response and Survival Outcomes in Patients with Advanced Cancer on Immune Checkpoint Inhibitors	3
TOPAZ-1: A New Standard of Care for Advanced Biliary Tract Cancers?	3
Immunotherapy Retreatment: Case Report, Review of the Literature and Proposal for the Definition of Different Scenarios	3
First-Line Chemotherapy Plus Immune Checkpoint Inhibitors or Bevacizumab in Advanced Non-Squamous Non-Small-Cell Lung Cancer without Egfr Mutations or Alk	3
Association Between Age and Efficacy of First-Line Immunotherapy-Based Combination Therapies for Mrcc: A Meta-Analysis	3
Multiple High-Grade and Rare Immune-Related Adverse Events in a Colon Cancer Patient with Genomic and Cytokine Profiling	3
Comparative Effectiveness of First-Line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors According to IMDC Risk Groups in Metastatic Renal Cell Carcinoma: A Meta-Analysis	3
Cost–Effectiveness of Camrelizumab Plus Chemotherapy in Advanced Squamous Non-Small-Cell Lung Cancer	3
A Case of Pembrolizumab-Induced Fulminant Type 1 Diabetes Mellitus in Breast Cancer	3
Identification of The Most Effective Subgroup Of Advanced Hepatocellular Carcinoma from Immune Checkpoint Blocker  Treatment: A Meta-Analysis	3
An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar	3
Pathologically Complete Remission to Combination of Invariant Nk T Cells and Anti-Cd20 Antibody in a Refractory Hiv+ Diffuse Large B-Cell Lymphoma Patient	3
Fatal Toxicity Induced by anti-PD-1 Immune Checkpoint Inhibitor in Thymic Epithelial Tumor	3
B Cells and Their Rolexs in Shaping the Immune Response in Squamous Cell Carcinoma of the Head and Neck	3
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement	3
Association Between PD-L1 Inhibitor, Tumor Site and Adverse Events of Potential Immune Etiology Within the US FDA Adverse Event Reporting System	3
Immune Checkpoint Inhibitor-Induced Neurologic Toxicity: A Case Report and Literature Review	3
Cost–effectiveness of Adjuvant Atezolizumab for Patients with Stage II–IIIA PD-L1+ Non-Small-Cell Lung Cancer	3
Efficacy of Subcutaneous House Dust Mite Immunotherapy in Patients with Moderate to Severe Allergic Rhinitis	3
Assessing Pd-L1 Status in Mrcc Treated with First-Line Immune-Based Combinations: A Meta-Analysis	3
Effect of Neoadjuvant Therapy on Tumor Tissue PD-L1 and VISTA Expression Levels in Non-Small-Cell Lung Cancer	3
Safety and Efficacy of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Focus on Challenging Populations	3
CT-P13 Subcutaneous Infliximab in Gastroenterology and Rheumatology	2
Tackling the Immunotherapy Conundrum: Advances and Challenges for Operable Non-Small-Cell Lung Cancer Treatment	2
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events	2
Immunotherapy in Neoadjuvant Setting in Muscle-Invasive Bladder Cancer, What’s New?	2
Neoadjuvant Immunotherapy Plus Chemotherapy and Adjuvant Targeted Therapy in ALK -Positive Non-Small-Cell Lung Cancer	2